1. Home
  2. |Insights
  3. |DCAA Issues Guidance On Revised Travel Cost Rule

DCAA Issues Guidance On Revised Travel Cost Rule

Client Alert | less than 1 min read | 04.12.10

In response to the recent revision to the travel cost rule at FAR 31.205-46(b) and (c), which now limits allowable airfare costs to the lowest airfare available to the contractor, DCAA issued guidance on March 22, 2010, that identifies the "lowest airfare available" as that available to the contractor through direct negotiation with airlines or travel agents. The guidance advises that contractors' policies and procedures should provide for (a) documented, advance planning of travel that considers nonrefundable airfares and lower airfares negotiated with airlines, travel service providers, and credit card companies and (b) obtaining quotations from competing airlines or travel service providers.

Insights

Client Alert | 9 min read | 10.21.26

Artificial Intelligence in Life Sciences: Reliability of AI-Generated Evidence in Drug Discovery and Development

The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .  ...